Bibliography
- SALITURO FG, GERMANN UA, WILSON KP et al: Inhibi- of p38 MAP kinase: therapeutic intervention in cytokine-mediated diseases. Curr. Med. Chem. (1999) 6:807–823.
- ••Excellent comprehensive review of the current p38 area byauthor from Vertex.
- GALLAGHER TF, SEIBEL GL, KASSIS S et al.: Regulation of stress-induced cytokine production by pyridinylimi-dazoles; inhibition of CSBP kinase. Bioorg. Med. Chem. (1997) 5:49–64.
- BADGER AM, BRADBEER JN, VOTTA B et al: Pharma-cological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function. J. Pharmacol Exp. Ther. (1996) 279:1453–1461.
- LEE JC, KASSIS S, KUMAR S et al.: p38 mitogen-activated protein kinase inhibitors - mechanisms and therapeutic potentials. Pharmacol Ther. (1999) 82:389–397.
- •Interesting survey of the SmithKline Beecham efforts on p38 with additional valuable references.
- HANSON GJ: Inhibitors of p38 kinase. Exp. Opin. Ther. Patents (1997) 7:729–733.
- BOEHM JC, ADAMS JL: New inhibitors of p38 kinase. Exp. Opin. Ther. Patents (2000) 10:729–733.
- ••Excellent review of the current patent literature on p38continuing on from where [5] left off.
- TONG L, PAV S, WHITE DM et al.: A highly specific of human p38 MAP kinase binds in the ATP pocket. Nature Struct. Biol. (1997) 4:311–316.
- •Crystal structure showing the binding site of an inhibitor to p38a kinase.